News

BioClinica buys into cost management with its latest deal

Acquisitive CRO BioClinica bought a firm that specializes in handling the financial side of clinical trials, picking up technology that automates how sponsors and contractors pay for studies.

Spotlight On... inVentiv opens new Phase I clinic; Pfizer taps Adaptive for immunotherapy R&D; and much more...

CRO inVentiv Health is expanding its early-stage research capabilities, opening a new Phase I clinic in Florida. The facility, sited at the University of Miami Life Science and Technology Park, has...

Evotec hits an R&D milestone with J&J in an ambitious Alzheimer's collaboration

Risk-sharing researcher Evotec said it's advancing an early-stage Alzheimer's disease project alongside partner Johnson & Johnson, working to find new approaches to treating the neurodegenerative disorder.

Eurofins buys Dutch drug-testing firm to pad its services

Luxembourg testing outfit Eurofins is deepening its work in biopharma, acquiring a specialist in drug testing headquartered in the Netherlands.

AMRI signs a trio of deals in R&D, manufacturing and marketing

Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.

Catalent inks a $619M deal to help Roche develop targeted therapies

Catalent Pharma Solutions is loaning out one of its drug development platforms to Roche in a heavily back-loaded deal, signing on to reap as much as $619 million.

Spotlight On... TxCell signs a CMO; BioDuro picks a CFO; and much more...

French biotech TxCell recruited Belgian contract manufacturer MaSTherCell to produce in-development T cell therapies under a 5-year agreement. More > San Diego CRO BioDuro appointed a new chief...

Altasciences rebrands its web of CROs in hopes of standing out

Canada's Altasciences is rebranding its three portfolio CROs in an effort to differentiate itself on the market for early-stage clinical research.

UCB taps Evotec to pitch in on drug discovery

Belgian drugmaker UCB recruited Evotec to oversee its library of chemical compounds, enlisting the German company's expertise in hopes of easing the drug discovery process.

Charles River spends $585M on WIL Research amid a buyout spree

Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.

PPD spins out its in-house biotech as sale rumors swirl

PPD, rumored to be up for sale, spun out its wholly owned biotech company into a stand-alone entity, a move the CRO said will maximize shareholder value.

Spotlight On... French CRO Porsolt buys a preclinical R&D firm; FDA launches new informatics platform; and much more...

Porsolt, a French contract drug researcher, bought a company focused on discovery-stage services. Acquiring the Bordeaux-headquartered Fluofarma, Porsolt is adding more capacity in cell-based assays,...

Outsourcer QPharma buys a sound-alike firm to help clients target key docs

QPharma, which makes its money handling launches for drugmakers, is investing in analytics, buying an unrelated company called Qforma to better target key physicians.

Quintiles' head of clinical development is retiring after 30 years

Paula Brown Stafford, a 30-year-veteran of Quintiles, is planning to retire from the world's largest CRO at the end of the year, wrapping up her tenure as president of clinical development.

PDI gets out of the contracting biz and embraces diagnostics

PDI, which long made its money helping drug companies outsource sales, is shipping off its banner business and shifting its focus to diagnostics.

TPG bets $75M on pharma service provider Precision for Medicine

Private equity giant TPG invested $75 million in Precision for Medicine, a recently formed company that partners with drugmakers to help them establish the value of in-development products.

Spotlight On... Capsugel buys a pair of CMOs; Shkreli arrested on fraud charges; and much more...

Contract manufacturer Capsugel signed a deal to buy a pair of smaller rivals in an effort to expand its capabilities in drug production. The company is paying an undisclosed sum for Xcelience and...

Recipharm signs on to manufacture an in-development cancer drug, investing in a Swedish biotech

Swedish contract drugmaker Recipharm is on board to help local biotech LIDDS advance its cancer therapy, agreeing to produce the drug and taking an equity stake in its partner.

On the rebound, AMRI trades $52M for a testing firm

AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.

PPD reportedly on the block for $8B

The private equity owners of CRO giant PPD are looking to either sell the company or take it public, according to Reuters, moves that would follow a trend in the pharma contracting industry.